tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

EXEL Stock Latest News

Exelixis price target raised to $46 from $45 at BofA
The FlyExelixis price target raised to $46 from $45 at BofA
1d ago
EXEL
Exelixis’s Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
PremiumRatings
Exelixis’s Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
1d ago
EXEL
Exelixis Holds Annual Meeting, Elects New Directors
PremiumCompany Announcements
Exelixis Holds Annual Meeting, Elects New Directors
4d ago
8K
EXEL
Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib
PremiumRatings
Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib
4d ago
EXEL
Exelixis’s Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating
PremiumRatings
Exelixis’s Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating
14d ago
EXEL
Promising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success
PremiumRatingsPromising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success
14d ago
EXEL
Exelixis announces results from expansion cohort of STELLAR-002 trial
Premium
The Fly
Exelixis announces results from expansion cohort of STELLAR-002 trial
15d ago
EXEL
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
21d ago
INM
XLO
Exelixis Q1 2025 Earnings Call Highlights Growth
PremiumCompany Announcements
Exelixis Q1 2025 Earnings Call Highlights Growth
22d ago
EXEL
Exelixis price target raised to $45 from $42 at Guggenheim
PremiumThe Fly
Exelixis price target raised to $45 from $42 at Guggenheim
22d ago
EXEL
Exelixis price target raised to $56 from $45 at Citi
PremiumThe Fly
Exelixis price target raised to $56 from $45 at Citi
22d ago
EXEL
Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
PremiumRatings
Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
22d ago
EXEL
Exelixis price target raised to $44 from $38 at TD Cowen
PremiumThe FlyExelixis price target raised to $44 from $38 at TD Cowen
23d ago
EXEL
Exelixis: Strong Financial Performance and Growth Potential Justify Buy Rating
Premium
Ratings
Exelixis: Strong Financial Performance and Growth Potential Justify Buy Rating
23d ago
EXEL
Exelixis price target raised to $47 from $40 at Morgan Stanley
Premium
The Fly
Exelixis price target raised to $47 from $40 at Morgan Stanley
23d ago
EXEL
Exelixis price target raised to $38 from $36 at Stifel
PremiumThe Fly
Exelixis price target raised to $38 from $36 at Stifel
23d ago
EXEL
Exelixis Hold Rating: Strong Performance and Promising Pipeline Balanced by Fair Valuation
PremiumRatings
Exelixis Hold Rating: Strong Performance and Promising Pipeline Balanced by Fair Valuation
23d ago
EXEL
Exelixis price target raised to $46 from $41 at Citizens JMP
PremiumThe Fly
Exelixis price target raised to $46 from $41 at Citizens JMP
23d ago
EXEL
Exelixis: Strong Financial Performance and Market Position Justify Buy Rating
PremiumRatings
Exelixis: Strong Financial Performance and Market Position Justify Buy Rating
23d ago
EXEL
Exelixis Reports Strong Q1 2025 Financial Performance
PremiumCompany AnnouncementsExelixis Reports Strong Q1 2025 Financial Performance
23d ago
EXEL
Exelixis: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Premium
Ratings
Exelixis: Strong Financial Performance and Promising Pipeline Drive Buy Rating
24d ago
EXEL
Exelixis’s Strong Financial Performance and Promising Pipeline Drive Optimistic Outlook and Increased Price Target
Premium
Ratings
Exelixis’s Strong Financial Performance and Promising Pipeline Drive Optimistic Outlook and Increased Price Target
24d ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >